



BLA 761291

BLA ACCELERATED APPROVAL

Janssen Biotech, Inc.
Attention: Nancy V. Nair, PharmD, MBA
Director, Global Regulatory Affairs
920 US Highway Route 202 South
Raritan, NJ 08869-0602

Dear Dr. Nair:

Please refer to your biologics license application (BLA) dated and received December 28, 2021, and your amendments, submitted under section 351(a) of the Public Health Service Act for Tecvayli (teclistamab-cqyv) injection.

We acknowledge receipt of your major amendment dated July 8, 2022, which extended the goal date by three months.

LICENSING

We have approved your BLA for Tecvayli (teclistamab-cqyv) effective this date. You are hereby authorized to introduce or deliver for introduction into interstate commerce, Tecvayli under your existing Department of Health and Human Services U.S. License No. 1864. Tecvayli is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

MANUFACTURING LOCATIONS

Under this license, you are approved to manufacture intermediate drug substance

(b) (4)
and at Janssen Biologics B.V. (JBV) in Leiden, The Netherlands; intermediate drug substance (b) (4) at Janssen Sciences Ireland UC (JSI) in Cork, Ireland; and teclistamab drug substance at JSI in Cork, Ireland. The final formulated product will be manufactured and filled a (b) (4)

(b) (4) and labeled and packaged at (b) (4) You may label your product with the proprietary name Tecvayli and will market it as a 30 mg/3 mL (10 mg/mL) solution in a single-dose vial, and as a 153 mg/1.7 mL (90 mg/mL) solution in a single-dose vial.

DATING PERIOD

The dating period for Tecvayli shall be 12 months from the date of manufacture when stored at 2°C to 8°C. The date of manufacture shall be defined as the date of final sterile filtration of the formulated drug product. The dating period for your drug substance shall be (b) (4) months from the date of manufacture when stored at (b) (4) °C. The dating period for your (b) (4) shall be (b) (4) months from the date of manufacture when stored at (b) (4) °C and for (b) (4) shall be (b) (4) months from the date of manufacture when stored at (b) (4) °C.

We have approved the stability protocols in your license application for the purpose of extending the expiration dating period of your intermediate substances, drug substance, and drug product under 21 CFR 601.12.

FDA LOT RELEASE

You are not currently required to submit samples of future lots of Tecvayli to the Center for Drug Evaluation and Research (CDER) for release by the Director, CDER, under 21 CFR 610.2. We will continue to monitor compliance with 21 CFR 610.1, requiring completion of tests for conformity with standards applicable to each product prior to release of each lot.

Any changes in the manufacturing, testing, packaging, or labeling of Tecvayli, or in the manufacturing facilities, will require the submission of information to your biologics license application for our review and written approval, consistent with 21 CFR 601.12.

APPROVAL AND LABELING

We have completed our review of this application, as amended. It is approved under the provisions of accelerated approval regulations (21 CFR 601.41), effective on the date of this letter, for use as recommended in the enclosed agreed-upon approved labeling. This BLA provides for the use of Tecvayli (teclistamab) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Marketing of this drug product and related activities must adhere to the substance and procedures of the referenced accelerated approval regulations.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at

FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Medication Guide). Information on submitting SPL files using eLIST may be found in the draft guidance for industry *SPL Standard for Content of Labeling Technical Qs and As* (October 2009).²

The SPL will be accessible via publicly available labeling repositories.

We request that the labeling approved today be available on your website within 10 days of receipt of this letter.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling submitted on August 5, 2022, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (February 2020, Revision 7)*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved BLA 761291.**” Approval of this submission by FDA is not required before the labeling is used.

ADVISORY COMMITTEE

Your application for Tecvayli was not referred to an FDA advisory committee because the application did not raise significant public health questions on the role of the biologic in the diagnosis, cure, mitigation, treatment, or prevention of a disease.

ACCELERATED APPROVAL REQUIREMENTS

Products approved under the accelerated approval regulations, 21 CFR 601.41, require further adequate and well-controlled clinical trials to verify and describe clinical benefit. You are required to conduct such clinical trials with due diligence. If postmarketing clinical trials fail to verify clinical benefit or are not conducted with due diligence, we may, following a hearing in accordance with 21 CFR 601.43(b), withdraw this approval. We remind you of your postmarketing requirement specified in your submission dated September 6, 2022. This requirement, along with required completion dates, is listed below.

- 4334-1 Conduct a randomized clinical trial in patients with relapsed or refractory multiple myeloma. The trial should enroll sufficient numbers of racial and

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² When final, this guidance will represent FDA’s current thinking on this topic. We update guidance periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

ethnic minority patients and older patients (ages 65-74 and 75 and above) to enable an evaluation of teclistamab in a study population that better reflects the U.S. population of patients with multiple myeloma. Patients should be randomized to receive a teclistamab-based regimen compared to standard therapy for relapsed or refractory multiple myeloma. The primary endpoint should be progression-free survival and secondary endpoints should include overall survival, overall response rate, and duration of response.

Draft Protocol Submission:	11/2022
Final Protocol Submission:	01/2023
Trial Completion:	09/2025
Final Report Submission:	03/2026

Submit clinical protocols to your IND 131272 for this product. In addition, under 21 CFR 601.70 you should include a status summary of each requirement in your annual report to this BLA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients entered into each study/trial.

Submit final reports to this BLA as a supplemental application. For administrative purposes, all submissions relating to this postmarketing requirement must be clearly designated “**Subpart E Postmarketing Requirement(s).**”

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for this application because the molecular target, B-cell maturation antigen (BCMA), is not substantially relevant to pediatric cancers and necessary studies are impossible or highly impracticable due to the extreme rarity of multiple myeloma in children and adolescents.

POSTMARKETING REQUIREMENTS UNDER 505(o)

Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act (FDCA) authorizes FDA to require holders of approved drug and biological product applications to conduct postmarketing studies and clinical trials for certain purposes, if FDA makes certain findings required by the statute.

We have determined that an analysis of spontaneous postmarketing adverse events reported under subsection 505(k)(1) of the FDCA will not be sufficient to assess a known serious risk of neurologic adverse events.

Furthermore, the active postmarket risk identification and analysis system as available under section 505(k)(3) of the FDCA will not be sufficient to assess this serious risk.

Finally, we have determined that only a clinical trial (rather than a nonclinical or observational study) will be sufficient to assess a known serious risk of neurologic toxicities.

Therefore, based on appropriate scientific data, FDA has determined that you are required to conduct the following trials:

- 4334-2 Conduct a clinical trial to further characterize and determine the incidence of neurologic toxicities in patients receiving teclistamab, including immune effector cell-associated neurotoxicity syndrome, encephalopathy, peripheral neuropathy including Guillain-Barré syndrome, and motor dysfunction including Parkinsonism. This data may come from Study 64007957MMY3001 (MajesTEC-3) and other clinical trials across the teclistamab development program including long term follow-up from Study 64007957MMY1001 (MajesTEC-1). Include the incidence rates, time to onset, and outcomes in the final report. Also include investigation of associations and temporal relationships between the incidence and severity of neurologic adverse events and potential associated risk factors, such as age and comorbidities.

The timetable you submitted on September 6, 2022, states that you will conduct this trial according to the following schedule:

Draft Protocol Submission (Analysis Plan):	04/2023
Final Protocol Submission (Analysis Plan):	10/2023
Trial Completion:	09/2025
Final Report Submission:	03/2026

FDA considers the term *final* to mean that the applicant has submitted a protocol, the FDA review team has sent comments to the applicant, and the protocol has been revised as needed to meet the goal of the study or clinical trial.³

Submit clinical protocol(s) to your IND 131272 with a cross-reference letter to this BLA. Submit nonclinical and chemistry, manufacturing, and controls protocols and all final report(s) to your BLA. Prominently identify the submission with the following wording in

³ See the FDA Draft Guidance for Industry *Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act* (October 2019). When finalized, the draft guidance will represent FDA's current thinking on this topic. For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/regulatoryinformation/search-fda-guidance-documents>

bold capital letters at the top of the first page of the submission, as appropriate:
Required Postmarketing Protocol Under 505(o), Required Postmarketing Final Report Under 505(o), Required Postmarketing Correspondence Under 505(o).

Section 505(o)(3)(E)(ii) of the FDCA requires you to report periodically on the status of any study or clinical trial required under this section. This section also requires you to periodically report to FDA on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Section 506B of the FDCA, as well as 21 CFR 601.70 requires you to report annually on the status of any postmarketing commitments or required studies or clinical trials.

FDA will consider the submission of your annual report under section 506B and 21 CFR 601.70 to satisfy the periodic reporting requirement under section 505(o)(3)(E)(ii) provided that you include the elements listed in 505(o) and 21 CFR 601.70. We remind you that to comply with 505(o), your annual report must also include a report on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Failure to submit an annual report for studies or clinical trials required under 505(o) on the date required will be considered a violation of FDCA section 505(o)(3)(E)(ii) and could result in enforcement action.

POSTMARKETING COMMITMENTS SUBJECT TO REPORTING REQUIREMENTS UNDER SECTION 506B

We remind you of your postmarketing commitments:

- 4334-3 Complete the MajesTEC-1 trial (Study 64007957MMY1001) to obtain the overall response rate and duration of response in enrolled patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody to further characterize efficacy of teclistamab monotherapy in this population.

The timetable you submitted on September 6, 2022, states that you will conduct this trial according to the following schedule:

Trial Completion:	12/2023
Final Report Submission:	06/2024

Submit the datasets with the final report submission.

POSTMARKETING COMMITMENTS NOT SUBJECT TO THE REPORTING REQUIREMENTS UNDER SECTION 506B

We remind you of your postmarketing commitments:

- 4334-4 Submit the final results for the low endotoxin recovery study performed to examine the effects of (b) (4) on endotoxin recovery using a

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov

known amount of standard endotoxin (CSE or RSE) [REDACTED]

(b) (4)

The timetable you submitted on September 1, 2022, states that you will conduct this study according to the following schedule:

Final Report Submission: 03/2023

Submit clinical protocols to your IND 131272 for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all postmarketing final reports to this BLA. In addition, under 21 CFR 601.70 you should include a status summary of each commitment in your annual progress report of postmarketing studies to this BLA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients/subjects entered into each study/trial. All submissions, including supplements, relating to these postmarketing commitments should be prominently labeled "**Postmarketing Commitment Protocol**," "**Postmarketing Commitment Final Report**," or "**Postmarketing Commitment Correspondence**."

RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS

Section 505-1 of the FDCA authorizes FDA to require the submission of a risk evaluation and mitigation strategy (REMS), if FDA determines that such a strategy is necessary to ensure that the benefits of the drug outweigh the risks.

In accordance with section 505-1 of FDCA, we have determined that a REMS is necessary for Tecvayli to ensure the benefits of the drug outweigh the risks of Cytokine Release Syndrome (CRS) and neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).

Your proposed REMS must also include the following:

Communication Plan: We have determined that a communication plan targeted to healthcare providers who are likely to prescribe and care for patients treated with Tecvayli (teclistamab-cqyv) will support implementation of the elements of your REMS. The communication plan provides for the dissemination of information about CRS and neurologic toxicity, including ICANS as well as requirements for prescriber certification and pharmacy or healthcare setting certification.

The communication plan must include, at minimum, the following:

- REMS Letter to Healthcare Providers and Professional Societies
- REMS Factsheet
- Dissemination of the REMS Letters and REMS Factsheet through field-based sales and medical representatives

Elements to assure safe use: Pursuant to 505-1(f)(1), we have also determined that Tecvayli (teclistamab-cqyv) can be approved only if elements necessary to assure safe use are required as part of the REMS to mitigate the risks of CRS and neurologic toxicity, including ICANS, listed in the labeling of the drug.

Your REMS includes the following elements to mitigate these risks:

- Healthcare providers have particular experience or training, or are specially certified
- Pharmacies and healthcare settings that dispense the drug are specially certified

Implementation System: The REMS must include an implementation system to monitor, evaluate, and work to improve the implementation of the elements to assure safe use (outlined above) that require pharmacies and health care settings that dispense the drug be specially certified.

Your proposed REMS, submitted on July 8, 2022, amended, and appended to this letter, is approved.

The REMS consists of a communication plan, elements to assure safe use, an implementation system, and a timetable for submission of assessments of the REMS.

Your REMS must be fully operational before you introduce Tecvayli (teclistamab-cqyv) into interstate commerce.

The REMS assessment plan must include, but is not limited to, the following:

Program Outreach and Communication Plan

1. REMS communication plan activities (provide data for the 1-year and 2-year assessments only):
 - a. Sources of the distribution lists for healthcare providers
 - b. Number of healthcare providers targeted stratified by specialty if known
 - c. Number of healthcare professional societies targeted, and which healthcare professional societies reported distribution of the REMS letter to their respective members
 - d. The number of packets of REMS materials sent by date, attempt, and method of distribution
 - e. The number and percentage of emails successfully delivered, opened, and unopened
 - f. The number and percentage of mail successfully delivered and returned as undeliverable

- g. The number of REMS Fact Sheets distributed to targeted healthcare providers during the 12 months after TECVAYLI is commercially distributed
- h. Date and name of the key scientific meetings attended and corresponding information on the REMS materials displayed

Program Implementation and Operations

- 2. Program Implementation (provide data at the 1-year assessment only):
 - a. Date of first commercial availability of TECVAYLI
 - b. Date the REMS Website went live
 - i. Number of total visits and unique visits to the REMS Website
 - ii. Number and type of TECVAYLI REMS materials downloaded or accessed
 - c. Date the REMS Coordinating Center was fully operational
 - d. Date prescribers and pharmacies/healthcare settings were able to complete the REMS certification process (online and by fax)
 - e. Date of the first prescriber certification
 - f. Date of the first pharmacy/healthcare setting certification
- 3. REMS Certification and Enrollment Statistics (provide data for two previous reporting periods, the current reporting period and cumulatively)
 - a. Healthcare Providers
 - i. Number of newly certified healthcare providers and number of active (i.e., who have prescribed TECVAYLI at least once during the reporting period) healthcare providers stratified by:
 - 1. Credentials (e.g., Doctor of Medicine, Doctor of Osteopathic Medicine, Nurse Practitioner, Physician Assistant, other)
 - 2. Specialty (e.g., Oncology, Hematology, Internal Medicine/Family Medicine, Other). If "other" accounts for > 10% of respondents for specialties, provide the most common specialties identified.
 - 3. Geographic region as defined by the US Census
 - 4. Method of enrollment (e.g., online, fax, e-mail) for newly certified healthcare providers only
 - ii. Number of incomplete prescriber enrollments, and summary of reported reason(s) for not completing
 - b. Pharmacies and Healthcare Settings

- i. Number of newly certified pharmacies/healthcare settings and number of active (i.e., who have dispensed or ordered the drug at least once during the reporting period) pharmacies/healthcare settings stratified by:
 - 1. Type of pharmacy/healthcare setting (e.g., Inpatient Hospital Pharmacy, Outpatient Hospital Pharmacy, Oncology Infusion Center, Community Oncology Physician Office, Other). If “other” accounts for > 10% of respondents for type, provide the most common type(s) identified.
 - 2. Geographic region as defined by the US Census
 - 3. Method of enrollment (e.g., online, fax, e-mail) for newly certified pharmacies/healthcare settings only
 - ii. Number of incomplete pharmacy/healthcare setting enrollments, and summary of reported reason(s) for not completing
- c. Wholesalers/distributors
 - i. Number of wholesalers/distributors contracted to ship and number of active (i.e., have shipped) wholesalers/distributors
- 4. Utilization Data (provide data for two previous reporting periods, the current reporting period and cumulatively)
 - a. Number of vials sent to certified pharmacies/healthcare settings, stratified by type of pharmacy/healthcare setting
 - b. Number and percentage of healthcare providers who wrote/ordered prescriptions that were dispensed, stratified by medical specialty (e.g., oncology) and provider credentials (e.g., Doctor of Medicine)
 - c. Number of dispense authorizations stratified by pharmacy/healthcare setting type
 - d. Number of RDAs rejected, stratified by:
 - i. Reasons and number of denials (numerator) divided by all denials (denominator)
 - 1. Healthcare provider not certified
 - 2. Other reasons for denial not categorized above
- 5. REMS Compliance (provide data for two previous reporting periods, the current reporting period and cumulatively)
 - a. Audits
 - i. A copy of the audit plan

- ii. Report of audit findings for each stakeholder
 - iii. Number of audits expected, and the number of audits performed
 - iv. Documentation of completion of training for relevant staff
 - v. Documentation of processes and procedures in place for complying with the TECVAYLI REMS
 - vi. Verification for each audited stakeholder's site that the designated Authorized Representative remains the same. If different, include the number of new Authorized Representatives
 - vii. Number and type of deficiencies noted for each group of audited stakeholders as a percentage of audited stakeholders
 - viii. Confirmation of documentation of completion of training for relevant staff after audit findings indicated training was necessary
 - ix. A comparison of the findings to findings of previous audits and an assessment of whether any trends are observed
- b. A copy of the Noncompliance Plan which addresses the criteria for noncompliance for each stakeholder (healthcare providers, pharmacies/healthcare settings and wholesalers-distributors), actions taken to address noncompliance for each event, and under what circumstances a stakeholder would be suspended or decertified from the REMS
- i. For those with deficiencies noted, report the number that successfully completed a Corrective and Preventive Actions (CAPA) plan within the timeframes specified in the Noncompliance Plan
 - ii. For any that did not complete the CAPA within the timeframe specified in the Noncompliance Plan, describe actions taken
 - iii. Number of instances of noncompliance accompanied by a description of each instance and the reason for the occurrence (if provided). For each instance of noncompliance, report the following information:
 - 1. Unique ID(s) of the stakeholder(s) associated with the noncompliance event or deviation to enable tracking over time
 - 2. Source of the noncompliance data
 - 3. Results of root cause analysis
 - 4. Action(s) that were taken in response

iv. Pharmacies/healthcare settings

1. Number of pharmacies/healthcare settings for which non-compliance with the TECVAYLI REMS is detected (numerator) divided by all pharmacies/healthcare settings dispensing TECVAYLI (denominator)
2. Number and description of pharmacies/healthcare settings that dispensed TECVAYLI to non-certified prescribers, and any corrective and preventative actions taken to prevent future occurrences
3. Number of non-certified pharmacies/healthcare settings that dispensed TECVAYLI (numerator) divided by all pharmacies/healthcare settings that dispensed TECVAYLI
4. Number of prescriptions dispensed by non-certified pharmacies/healthcare settings (numerator) divided by all TECVAYLI prescriptions dispensed (denominator) and the actions taken to prevent future occurrences
5. Summary of audit findings and any action taken and outcome of actions to prevent future occurrences
6. Summary of findings for monitoring conducted during the reporting period, including any CAPA

v. Wholesalers/Distributors

1. Number and description of non-certified pharmacies/healthcare settings that were shipped TECVAYLI, and the number of these that subsequently became certified
2. The number of authorized wholesalers-distributors for which non-compliance with the REMS is detected (numerator) divided by the number of contracted wholesalers-distributors (denominator)
3. The number and type of wholesalers-distributors not contracted with Janssen that shipped TECVAYLI and the number of incidents for each
4. The number of contracted wholesalers-distributors suspended and/or unauthorized to distribute for non-compliance with REMS requirements and reasons for such actions

c. Any other TECVAYLI REMS noncompliance, source of report and resulting CAPA

6. REMS Coordinating Center Report (provide data for two previous reporting periods, the current reporting period and cumulatively)

- a. Number of contacts by stakeholder type (patient/caregiver, certified prescriber, pharmacy/healthcare setting authorized representative or staff, other HCP, wholesaler/distributor, other)
- b. Summary of the reasons for the call(s) by stakeholder type. Limit the summary to the top five reasons for calls by stakeholder group
- c. Description of each call, including stakeholder credentials, that may indicate an issue with product access due to the REMS program, REMS program burden or adverse event
- d. If the summary reason for the call(s) indicates an adverse event related to Cytokine Release Syndrome (CRS) or neurologic toxicity including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) include details and the outcome of the call(s)
- e. Provide an assessment for any reports to the REMS Coordinating Center indicating a burden to the healthcare system or barrier(s) to patient access. Include in the assessment whether the burden or access issue is attributable to the REMS, insurance, health care availability, other
- f. Summary of frequently asked questions (FAQ) by stakeholder credentials type. Limit the summary to the top five FAQs for calls by stakeholder group
- g. Summary of any noncompliance that is identified through coordinating center contacts, source of report and resulting CAPA
- h. Summary of CAPAs resulting from issues identified
- i. Percentage of calls to the REMS Coordinating Center that were answered within 20 minutes
- j. The shortest wait time for a call to be answered, the longest wait time for a call to be answered and the median time for a call to be answered
- k. Percentage of calls to the REMS Coordinating Center where the caller abandoned the call before the call was answered
- l. The shortest wait time at which a call was abandoned, the longest wait time before the call was abandoned and the median wait time for a call to be abandoned

Knowledge

7. Knowledge Assessment (provide data for two previous reporting periods, the current reporting period and cumulatively)
 - a. Number of completed healthcare provider Knowledge Assessments, including the method of completion

- b. Summary statistics, including mean number of attempts, score, and range of scores and number of attempts to successfully complete the Knowledge Assessment
 - c. Summary of most frequently missed questions on the Knowledge Assessment
 - d. A summary of potential comprehension or perception issues identified with the Knowledge Assessment
- 8. Periodic Survey of Certified Prescribers (beginning with the 1-Year REMS Assessment Report and thereafter with each assessment report)

A Knowledge, Attitude and Behavior (KAB) Survey will be conducted with random samples of healthcare providers who prescribe TECVAYLI

- a. Evaluation of understanding of the risks and mitigation strategies of the TECVAYLI REMS as well as compliance with the mitigation strategies
 - b. An evaluation of prescriber's knowledge on the importance of monitoring patients for signs and symptoms of CRS and neurologic toxicity including ICANS
- 9. Report on Key Performance Indicators: The key performance indicators (KPI), or the primary metrics that will be used to evaluate the TECVAYLI REMS, include a process indicator (REMS operations) and an outcome indicator (REMS evaluation of the primary objective)
 - a. REMS Operations: 99.9% of dispensed prescriptions were authorized by the REMS prior to dispense. REMS authorization for dispense requires both the prescriber and the pharmacy/healthcare setting be certified
 - b. REMS Evaluation of the objective: $\geq 80\%$ of prescriber KAB survey respondents demonstrated knowledge of the importance of monitoring patients for signs and symptoms of CRS and neurologic toxicity including ICANS

Health Outcomes and/or Surrogates of Health Outcomes

- 10. A summary analysis of all reported cases of CRS and neurologic toxicity including ICANS, stratified by source of report (i.e., spontaneous). (Provide data for two previous reporting periods, the current reporting period and cumulatively)
 - a. Include the following stratifications by grade/severity in the analysis
 - i. Step-up dosing was initiated in the hospital setting. (For those reports that indicate initiation outside of the hospital setting provide the setting if known)
 - ii. Pre-medication was administered

The requirements for assessments of an approved REMS under section 505-1(g)(3) include with respect to each goal included in the strategy, an assessment of the extent to which the approved strategy, including each element of the strategy, is meeting the goal or whether 1 or more such goals or such elements should be modified.

If the information provided in an assessment is insufficient to allow FDA to determine whether the REMS is meeting its goals or whether the REMS must be modified, FDA may require the submission of a new assessment plan that contains the metrics and/or methods necessary to make such a determination. Therefore, FDA strongly recommends obtaining FDA feedback on the details of your proposed assessment plan to ensure its success. To that end, we recommend that methodological approaches, study protocols, other analysis plans and assessment approaches used to assess a REMS program be submitted for FDA review as follows:

- i. Submit your proposed protocol for the knowledge survey for FDA review within 90 days of this letter.

Prominently identify the submission containing the assessment instruments and methodology with the following wording in bold capital letters at the top of the first page of the submission:

BLA 761291 REMS ASSESSMENT METHODOLOGY

(insert concise description of content in bold capital letters, e.g.,

ASSESSMENT METHODOLOGY, PROTOCOL, SURVEY METHODOLOGIES, AUDIT PLAN, DRUG USE STUDY)

We remind you that in addition to the REMS assessments submitted according to the timetable in the approved REMS, you must include an adequate rationale to support a proposed REMS modification for the addition, modification, or removal of any goal or element of the REMS, as described in section 505-1(g)(4) of the FDCA.

We also remind you that you must submit a REMS assessment when you submit a supplemental application for a new indication for use as described in section 505-1(g)(2)(A). This assessment should include:

- a) An evaluation of how the benefit-risk profile will or will not change with the new indication.
- b) A determination of the implications of a change in the benefit-risk profile for the current REMS.
- c) *If the new, proposed indication for use introduces unexpected risks:* A description of those risks and an evaluation of whether those risks can be appropriately managed with the currently approved REMS.

- d) *If a REMS assessment was submitted in the 18 months prior to submission of the supplemental application for a new indication for use:* A statement about whether the REMS was meeting its goals at the time of the last assessment and if any modifications of the REMS have been proposed since that assessment.
- e) *If a REMS assessment has not been submitted in the 18 months prior to submission of the supplemental application for a new indication for use:* Provision of as many of the currently listed assessment plan items as is feasible.
- f) *If you propose a REMS modification based on a change in the benefit-risk profile or because of the new indication of use, submit an adequate rationale to support the modification, including:* Provision of the reason(s) why the proposed REMS modification is necessary, the potential effect on the serious risk(s) for which the REMS was required, on patient access to the drug, and/or on the burden on the health care delivery system; and other appropriate evidence or data to support the proposed change. Additionally, include any changes to the assessment plan necessary to assess the proposed modified REMS. *If you are not proposing a REMS modification, provide a rationale for why the REMS does not need to be modified.*

Prominently identify any submission containing the REMS assessments or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission as appropriate:

BLA 761291 REMS ASSESSMENT

or

**NEW SUPPLEMENT FOR BLA 761291/S-000
CHANGES BEING EFFECTED IN 30 DAYS
PROPOSED MINOR REMS MODIFICATION**

or

**NEW SUPPLEMENT FOR BLA 761291/S-000
PRIOR APPROVAL SUPPLEMENT
PROPOSED MAJOR REMS MODIFICATION**

or

**NEW SUPPLEMENT FOR BLA 761291/S-000
PRIOR APPROVAL SUPPLEMENT
PROPOSED REMS MODIFICATIONS DUE TO SAFETY LABELING
CHANGES SUBMITTED IN SUPPLEMENT XXX**

or

**NEW SUPPLEMENT (NEW INDICATION FOR USE)
FOR BLA 761291/S-000
REMS ASSESSMENT
PROPOSED REMS MODIFICATION (if included)**

Should you choose to submit a REMS revision, prominently identify the submission containing the REMS revisions with the following wording in bold capital letters at the top of the first page of the submission:

REMS REVISION FOR BLA 761291

To facilitate review of your submission, we request that you submit your proposed modified REMS and other REMS-related materials in Microsoft Word format. If certain documents, such as enrollment forms, are only in PDF format, they may be submitted as such, but the preference is to include as many as possible in Word format.

SUBMISSION OF REMS DOCUMENT IN SPL FORMAT

FDA can accept the REMS document in Structured Product Labeling (SPL) format. If you intend to submit the REMS document in SPL format, as soon as possible, but no later than 14 days from the date of this letter, submit the REMS document in SPL format using the FDA automated drug registration and listing system (eLIST).

For more information on submitting REMS in SPL format, please email FDAREMSwebsite@fda.hhs.gov.

PROMOTIONAL MATERIALS

Under 21 CFR 601.45, you are required to submit, during the application pre-approval review period, all promotional materials, including promotional labeling and advertisements, that you intend to use in the first 120 days following marketing approval (i.e., your launch campaign). If you have not already met this requirement, you must immediately contact the Office of Prescription Drug Promotion (OPDP) at (301) 796-1200. Please ask to speak to a regulatory project manager or the appropriate reviewer to discuss this issue.

As further required by 21 CFR 601.45, submit all promotional materials that you intend to use after the 120 days following marketing approval (i.e., your post-launch materials) at least 30 days before the intended time of initial dissemination of labeling or initial publication of the advertisement. We ask that each submission include a detailed cover letter together with three copies each of the promotional materials, annotated references, and approved Prescribing Information, Medication Guide, and Patient Package Insert (as applicable).

For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.⁴

REPORTING REQUIREMENTS

You must submit adverse experience reports under the adverse experience reporting requirements for licensed biological products (21 CFR 600.80).

Prominently identify all adverse experience reports as described in 21 CFR 600.80.

You must submit distribution reports under the distribution reporting requirements for licensed biological products (21 CFR 600.81).

You must submit reports of biological product deviations under 21 CFR 600.14. You should promptly identify and investigate all manufacturing deviations, including those associated with processing, testing, packing, labeling, storage, holding and distribution. If the deviation involves a distributed product, may affect the safety, purity, or potency of the product, and meets the other criteria in the regulation, you must submit a report on Form FDA 3486 to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Compliance Risk Management and Surveillance
5901-B Ammendale Road
Beltsville, MD 20705-1266

Biological product deviations, sent by courier or overnight mail, should be addressed to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Compliance Risk Management and Surveillance
10903 New Hampshire Avenue, Bldg. 51, Room 4207
Silver Spring, MD 20903

POST APPROVAL FEEDBACK MEETING

New molecular entities and new biologics qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

⁴ <https://www.fda.gov/media/128163/download>

If you have any questions, call, Denise Felluca, Regulatory Project Manager, at 301-796-4574 or denise.felluca@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Marc Theoret, MD
Supervisory Associate Director (Acting)
Office of Oncologic Diseases
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information
 - Medication Guide
- Carton and Container Labeling
- REMS

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

MARC R THEORET
10/25/2022 10:46:45 AM